A noninvasive urinary biomarker panel predicts lupus nephritis activity and response better than proteinuria, and, if further validated, may aid diagnosis and gauge treatment response, investigators ...

Deuruxolitinib showed significant efficacy and safety in hair regrowth stimulation among adult patients with alopecia areata, ...

The Phase I trial of the combination therapy saw a an approximate 66% rate of near-complete remission in its cohort of breast ...

About 33% of ocular tuberculosis patients may relapse within 2 years of achieving clinical inactivity, with a poor initial ...

In recent decades, immunotherapy has transformed cancer treatment, offering effective options for diseases once considered ...

The following is a summary of “Type I interferon biomarker in idiopathic inflammatory myopathies: associations of Siglec-1 ...

The Wistar Institute has unveiled a groundbreaking approach to tackling ovarian cancer, potentially revolutionizing treatment ...

The Wistar Institute's Nan Zhang, Ph.D., assistant professor in the Ellen and Ronald Caplan Cancer Center's Molecular and ...

Building on this concept, Zhang & team designed an approach that specifically activates myeloid cells within the peritoneal cavity through combination treatment with ß-glucan, a pathogen-derived ...

On Friday, Vir Biotechnology, Inc. (NASDAQ:VIR) announced end-of-treatment data from Part B of the MARCH Phase 2 study ...